We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+13.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$3.33M
(+1.5%)
Cap. Flow
-$9.09M
Cap. Flow
% of AUM
-4.16%
Top 10 Holdings %
Top 10 Hldgs %
53.49%
Holding
80
New
23
Increased
12
Reduced
26
Closed
8
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Radius Health, Inc.
RDUS
|
+$4.26M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$3.77M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$3.35M |
| 4 |
Sage Therapeutics
SAGE
|
+$3.05M |
| 5 |
Sanofi
SNY
|
+$2.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABLX
Ablynx NV
ABLX
|
+$9.92M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$9.66M |
| 3 |
The Ensign Group
ENSG
|
+$5.27M |
| 4 |
Array Biopharma Inc
ARRY
|
+$4.92M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$3.72M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.69% |
| 2 | Real Estate | 11.35% |
| 3 | Industrials | 8.34% |
| 4 | Miscellaneous | 6.63% |
| 5 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
EPZM
51
DELISTED
Epizyme, Inc
EPZM
| $643K | 0.29% |
47,449
-10,000
| -17% | -$156K |
2018 Q1
1 quarter
|
|
|
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
| $640K | 0.29% |
18,029
| – | – |
2018 Q1
1 quarter
|
|
53
DELISTED
Affimed
AFMD
| $638K | 0.29% |
38,686
| – | – |
2018 Q1
1 quarter
|
|
|
GBT
54
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $624K | 0.29% |
13,800
-4,000
| -22% | -$182K |
2017 Q4
2 quarters
|
|
|
FOMX
55
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $539K | 0.25% |
107,500
| – | – |
2018 Q1
1 quarter
|
|
|
MLNT
56
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $488K | 0.22% |
15,367
| – | – |
2018 Q1
1 quarter
|
|
|
IIN
57
DELISTED
IntriCon Corporation
IIN
| $484K | 0.22% |
+12,000
| New | +$360K |
2018 Q2
0 quarters
|
|
|
ZGNX
58
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $442K | 0.2% |
+10,000
| New | +$412K |
2018 Q2
0 quarters
|
|
|
QCP
59
CALL
DELISTED
Quality Care Properties, Inc.
QCP
| $430K | 0.2% |
+20,000
| New | +$422K |
2018 Q2
0 quarters
|
|
60
DELISTED
MODEL N, INC.
MODN
| $418K | 0.19% |
+22,461
| New | +$396K |
2018 Q2
0 quarters
|
|
61
DELISTED
Dynavax Technologies
DVAX
| $412K | 0.19% |
27,000
-3,000
| -10% | -$51.9K |
2018 Q1
1 quarter
|
|
|
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $407K | 0.19% |
149,100
| – | – |
2017 Q4
2 quarters
|
|
63
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $394K | 0.18% |
+100,402
| New | +$348K |
2018 Q2
0 quarters
|
|
|
SPNE
64
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $390K | 0.18% |
30,899
| – | – |
2017 Q4
2 quarters
|
|
|
CYAD
65
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
| $382K | 0.17% |
+12,840
| New | +$394K |
2018 Q2
0 quarters
|
|
66
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $375K | 0.17% |
9,536
-75,554
| -89% | -$2.22M |
2018 Q1
1 quarter
|
|
67
iRadimed
IRMD
$1.13B
| $365K | 0.17% |
17,608
-33,451
| -66% | -$591K |
2017 Q4
2 quarters
|
|
|
MGLN
68
DELISTED
Magellan Health Services, Inc.
MGLN
| $288K | 0.13% |
3,000
-6,282
| -68% | -$602K |
2017 Q4
2 quarters
|
|
69
DELISTED
Dermira, Inc.
DERM
| $184K | 0.08% |
20,018
| – | – |
2018 Q1
1 quarter
|
|
|
CFMS
70
DELISTED
Conformis, Inc. Common Stock
CFMS
| $159K | 0.07% |
+5,074
| New | +$175K |
2018 Q2
0 quarters
|
|
71
Eocene Ltd. Ordinary Shares
EOCN
$3.04M
| $119K | 0.05% |
+7
| New | +$81.1K |
2018 Q2
0 quarters
|
|
|
QCP
72
PUT
DELISTED
Quality Care Properties, Inc.
QCP
| $38.7K | 0.02% |
+1,800
| New | +$38K |
2018 Q2
0 quarters
|
|
73
Align Technology
ALGN
$10.5B
| – | – |
-3,000
| Closed | -$753K | – |
|
74
CALL
MiMedx Group
MDXG
$646M
| – | – |
-48,000
| Closed | -$335K | – |
|
75
Neurogene
NGNE
$465M
| – | – |
-1,599
| Closed | -$450K | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2018 Portfolio in Review
As of Q2 2018, Eversept Partners held 80 positions worth $219M, up 1.5% from $215M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Eversept Partners withdrew a net $9.09M in Q2 2018, closing 8 positions and reducing 26 holdings. Its most notable exit was Ablynx NV, an estimated $9.92M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Real Estate and Industrials.
Against the trend, Eversept Partners opened a new position in Sarepta Therapeutics worth $5.29M.
- Eversept Partners's largest Q2 2018 buy was Sarepta Therapeutics: 40,000 shares worth $5.29M.
- Eversept Partners added most to Radius Health, Inc. in Q2 2018, an estimated $4.26M increase.
- Eversept Partners's biggest Q2 2018 reduction was The Ensign Group, cutting an estimated $5.27M.
- Eversept Partners fully exited Ablynx NV in Q2 2018, selling an estimated $9.92M.
- Eversept Partners's ten largest holdings make up 53% of its $219M portfolio in Q2 2018.
- Eversept Partners opened 23 new positions and closed 8 in Q2 2018.
- Eversept Partners's portfolio value rose 1.5% quarter-over-quarter to $219M.
Based on Eversept Partners's 13F filing for Q2 2018, filed 14 Aug 2018.